Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial.

Sirolimus-eluting balloon with provisional stenting is noninferior to systematic drug-eluting stent implantation for target vessel failure at 1 year in de novo coronary lesions.

• Why it matters: Long-term adverse events from drug-eluting stents highlight the need for alternative strategies that minimize stent use and potential complications in coronary interventions.
• What they did: A multicenter, randomized trial compared a sirolimus-eluting balloon strategy with provisional stenting to systematic drug-eluting stent placement in 3323 patients, assessing target vessel failure over one year.
• The result: The sirolimus-eluting balloon approach demonstrated noninferiority in target vessel failure rates, though it had higher revascularization rates, supporting its potential as a less stent-dependent treatment option.